Neurocrine Biosciences, Inc.


Market Cap$13.71B

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Neurocrine Biosciences, Inc.Neurocrine Biosciences, Inc.37.10%15%7.10.1

Target Price by Analysts

28.2% upsideNeurocrine Biosciences Target Price DetailsTarget Price

Current Fair Value

86.5% upside

Undervalued by 86.5% based on the discounted cash flow analysis.

Share Statistics

Market cap$13.71 Billion
Enterprise Value$12.63 Billion
Dividend Yield$0.0 (0.0%)
Earnings per Share$3.6
Outstanding Shares100,637,227
Avg 30 Day Volume774,113


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio37.09
Price to Sales7.06
Price to Book Ratio5.83
Enterprise Value to Revenue6.37
Enterprise Value to EBIT26.84
Enterprise Value to Net Income34
Total Debt to Enterprise0.01
Debt to Equity0.05

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Neurocrine Biosciences, Inc.

CEO: Kevin Gorman